Neridronic acid
As of the edition of 20 October 2026, Neridronic acid is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Nerixia
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Abiogen Pharma S.P.A.
- Registered trials
- 7, 2 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Blood and lymph; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 0 | 0 |
| Phase 3 | 5 | 2 | 1 | 2 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Grünenthal | Lead sponsor of trials | 2015 to now |
| Ambros Therapeutics | Lead sponsor of trials | 2026 to now |